Citation Impact
Citing Papers
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2011 Standout
Normal gut microbiota modulates brain development and behavior
2011 Standout
Deep Brain Stimulation for Treatment-Resistant Depression
2005 Standout
Differential Response to Combined Treatment in Patients With Psychotic Versus Nonpsychotic Major Depression
2005
The Medical Management of Depression
2005
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care
2007
Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents
2007
Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application
2006
Cognitive Function Across Manic or Hypomanic, Depressed, and Euthymic States in Bipolar Disorder
2004 Standout
Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics
2003
Depression
2018 Standout
Augmentation of Antidepressants with Atypical Antipsychotics: A Review of the Current Literature
2008
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting
2009
Olanzapine in the Treatment of Refractory Migraine and Chronic Daily Headache
2002
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders
2015
Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or Cul‐de‐sac?
2007
RIM1α and Interacting Proteins Involved in Presynaptic Plasticity Mediate Prepulse Inhibition and Additional Behaviors Linked to Schizophrenia
2010 StandoutNobel
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
2010 Standout
Atopic Dermatitis
2008 Standout
Targeting the dopamine D2receptor in schizophrenia
2006
Comparison of systematic and narrative reviews: the example of the atypical antipsychotics
2003
Differential effects of adjunctive methylphenidate and citalopram on extracellular levels of serotonin, noradrenaline and dopamine in the rat brain
2007
Comparative efficacy of antipsychotics in the treatment of schizophrenia: A critical assessment
2005
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
2005 Standout
Neuropathology of mitral valve prolapse in man and cardiopulmonary bypass (CPB) surgery in adolescent Yorkshire pigs
2000 StandoutNobel
Olanzapine Treatment of Psychotic and Behavioral Symptoms in Patients With Alzheimer Disease in Nursing Care Facilities
2000
Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs
2004
Schizophrenia and the α7 Nicotinic Acetylcholine Receptor
2007
Antipsychotic agents in the treatment of bipolar mania
2009
Schizophrenia
2009 Standout
Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study
2005
Functional Selectivity and Classical Concepts of Quantitative Pharmacology
2006 StandoutNobel
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
2013 Standout
Prevalence of Neuropsychiatric Symptoms in Dementia and Mild Cognitive Impairment
2002 Standout
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
2015 Standout
Effects of Olanzapine, Quetiapine, and Risperidone on Neurocognitive Function in Early Psychosis: A Randomized, Double-Blind 52-Week Comparison
2007
Changes in Diet and Lifestyle and Long-Term Weight Gain in Women and Men
2011 Standout
Network pharmacology: the next paradigm in drug discovery
2008 Standout
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance
2012
Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis
2015
Glutamatergic dysfunction in schizophrenia: From basic neuroscience to clinical psychopharmacology
2008
A Placebo-Controlled Add-On Trial of the Ampakine, CX516, for Cognitive Deficits in Schizophrenia
2007
Publication Bias in Antipsychotic Trials: An Analysis of Efficacy Comparing the Published Literature to the US Food and Drug Administration Database
2012
Versión española de una escala de evaluación de la manía: validez y fiabilidad de la Escala de Young
2002
A Double-Blind, Randomized, Placebo-Controlled Study of Quetiapine as Adjunctive Treatment for Adolescent Mania
2002
What Happened to Lithium? Antidepressant Augmentation in Clinical Settings
2006
Handling drop‐out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches
2007
Effects of the CRF1 receptor antagonist, CP 154,526, in the separation-induced vocalization anxiolytic test in rat pups
2000
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
2005 Standout
What Is a “Mood Stabilizer”? An Evidence-Based Response
2004
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
2013 Standout
Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone
2003
Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
2011 Standout
Psychosis as a State of Aberrant Salience: A Framework Linking Biology, Phenomenology, and Pharmacology in Schizophrenia
2002 Standout
Cognitive Improvement After Treatment With Second-Generation Antipsychotic Medications in First-Episode Schizophrenia
2007
Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
2003
The Physiology, Signaling, and Pharmacology of Dopamine Receptors
2011 Standout
Bipolar Disorder
2004
Current Issues in the Classification of Psychotic Major Depression
2007
A β-arrestin 2 Signaling Complex Mediates Lithium Action on Behavior
2008 StandoutNobel
"Schizotaxia": Clinical Implications and New Directions for Research
2001
Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement
1999 Standout
Rethinking schizophrenia
2010 StandoutNature
Power failure: why small sample size undermines the reliability of neuroscience
2013 Standout
Flupenthixol versus Risperidone: Subjective Quality of Life as an Important Factor for Compliance in Chronic Schizophrenic Patients
2003
Alzheimer's disease
2006 Standout
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis
2009 Standout
Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2
2009
Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range
2014 Standout
Shaking the tree: mapping complex disease genes with linkage disequilibrium
2005
Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study
2009
Functional mapping and annotation of genetic associations with FUMA
2017 Standout
Major Depressive Disorder
2008 Standout
Mental health of young people: a global public-health challenge
2007 Standout
Consensus Statement on Management of Intersex Disorders
2006 Standout
The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches
2001
Five-Year Follow-up of a Randomized Multicenter Trial of Intensive Early Intervention vs Standard Treatment for Patients With a First Episode of Psychotic Illness
2008
Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis
1999 Standout
Utility of Atypical Antipsychotics in the Treatment of Resistant Unipolar Depression
2009
Dietary energy density in the treatment of obesity: a year-long trial comparing 2 weight-loss diets
2007
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials
1999
ALZHEIMER'S DISEASE AND RELATED DISORDERS
2001
Alzheimer's Disease
2004 Standout
The new and evolving pharmacotherapy of schizophrenia
2003
An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia
2004
How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials
2008
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
A Summary of the FDA-NIMH-MATRICS Workshop on Clinical Trial Design for Neurocognitive Drugs for Schizophrenia
2005
Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life
2000
Subjective experience and mental side‐effects of antipsychotic treatment
1999
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
2013 Standout
The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies
2001 Standout
Safety of Available Agents Used to Treat Bipolar Disorder
2003
Maternal mortality: who, when, where, and why
2006 Standout
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
2003
Adherence to Medication
2005 Standout
Antipsychotics in Adults With Schizophrenia: Comparative Effectiveness of First-Generation Versus Second-Generation Medications
2012
Fluorine in medicinal chemistry
2007 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Imputation methods for missing outcome data in meta-analysis of clinical trials
2008
Abnormal neural oscillations and synchrony in schizophrenia
2010 Standout
Risperidone versus typical antipsychotic medication for schizophrenia
2003
Pharmacological interventions for somatoform disorders in adults
2014 Standout
Practice parameter: Management of dementia (an evidence-based review) [RETIRED]
2001 Standout
Negative Signs and Symptoms Secondary to Antipsychotics: A Double-Blind, Randomized Trial of a Single Dose of Placebo, Haloperidol, and Risperidone in Healthy Volunteers
2006
What Happened to Lithium? Antidepressant Augmentation in Clinical Settings
2006
The differential effects of chlorpromazine and haloperidol on latent inhibition in healthy volunteers
2001
Fluorine in Pharmaceuticals: Looking Beyond Intuition
2007 StandoutScience
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial
1997
3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as High Affinity, Selective, and Orally Bioavailable h5-HT2A Receptor Antagonists
2001
Interventions for enhancing medication adherence
2014 Standout
Effects on prolongation of Bazett’s corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis
2010
A systematic review of atypical antipsychotic drugs in schizophrenia
2003
Atypical Antipsychotics: New Directions and New Challenges in the Treatment of Schizophrenia
2001
Haloperidol versus placebo for schizophrenia
2013
Reported Methodologic Quality and Discrepancies between Large and Small Randomized Trials in Meta-Analyses
2001 Standout
CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials
2010 Standout
Systematic reviews: CRD's guidance for undertaking reviews in health care
2010 Standout
Works of T.M. Sanger being referenced
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression
2006
A Double-Blind, Randomized Study of Olanzapine and Olanzapine/Fluoxetine Combination for Major Depression With Psychotic Features
2004
A Randomized, Double-Blind Comparison of Olanzapine/Fluoxetine Combination, Olanzapine, and Fluoxetine in Treatment-Resistant Major Depressive Disorder
2007
Olanzapine Plasma Concentrations and Clinical Response: Acute Phase Results of the North American Olanzapine Trial
2001
Long-Term Neurocognitive Effects of Olanzapine or Low-Dose Haloperidol in First-Episode Psychosis
2005
Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial
1996
Comparative Effect of Atypical and Conventional Antipsychotic Drugs on Neurocognition in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine Versus Low Doses of Haloperidol
2004
A meta-analysis of the use of typical antipsychotic agents in bipolar disorder
2001
Olanzapine Versus Haloperidol Treatment in First-Episode Psychosis
1999
Olanzapine Versus Placebo in the Treatment of Acute Mania
1999
Long-Term Olanzapine Therapy in the Treatment of Bipolar I Disorder
2001
Assessing and interpreting treatment effects in longitudinal clinical trials with missing data
2003
Olanzapine/Fluoxetine Combination for Treatment-Resistant Depression
2005
Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling
2002
Olanzapine versus Placebo and Haloperidol
1996
A Double-Blind, Controlled Comparison of the Novel Antipsychotic Olanzapine versus Haloperidol or Placebo on Anxious and Depressive Symptoms Accompanying Schizophrenia
1998
Depressive Signs and Symptoms in Schizophrenia
1998
Long-Term Antidepressant Efficacy and Safety of Olanzapine/Fluoxetine Combination
2003
Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol
1998
Olanzapine: Acute and long-term efficacy in bipolar I patients
2000
The course of primary and secondary negative symptoms in a placebo-and comparator-controlled trial of the typical antipsychotic olanzapine
1996
Is olanzapine a mood-stabilizer?
2000
The course of primary and secondary negative symptoms in a controlled trial with olanzaplne
1996
Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders
1998
The course of primary and secondary negative symptoms in a controlled trial with olanzapine
1997
Olanzapine versus haloperidol in the treatment of first episode psychosis
1998
Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine
1997
Long-term olanzapine treatment: Efficacy and safety in manic patients with and without psychotic features
1999
Olanzapine-fluoxetine combination in treatment-resistant depression
2002
Onset of action of olanzapine-fluoxetine combination for bipolar depression
2002
Reduction of psychotic symptoms in patients with lewy body-like symptoms treated with olanzapine
2000
Olanzapine vs. placebo in rapid-cycling bipolar disorder
1998